Skip to main content

Table 4 Comparison between the imaging arm and clinical arm of the ASAS axSpA criteria, with the required presence of HLA-B27 and imaging

From: The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study

  Imaging arm (%), HLA-B27 always available Clinical arm alone (%), imaging always available (n = 98)
HLA-B27-positive (n = 1746) HLA-B27-negative (n = 546)
Age, years 40.3 (13.0) 42.7 (13.0) 42.8 (13.0)
Male sex 1294 (74.1%) 275 (50.4%) 52 (53.1)
IBP 1639 (93.3%) 529 (96.9%) 87 (88.8%)
Peripheral arthritis 904 (51.8%) 302 (55.3%) 57 (58.2%)
Psoriasis 147 (8.4%) 105 (19.2%) 14 (14.3%)
Uveitis 453 (25.9%) 49 (9.0%) 27 (27.6%)
Enthesitis 563 (32.2%) 164 (30.0%) 44 (44.9%)
Dactylitis 137 (7.8%) 55 (10.1%) 17 (17.3%)
IBD 73 (4.2%) 46 (8.4%) 6 (6.1%)
Positive family history 669 (38.3%) 166 (30.4%) 52 (53.1%)
Good response to NSAIDs 1180 (67.6%) 265 (48.5%) 64 (65.3%)
Elevated CRP 1094 (62.7%) 256 (46.9%) 41 (41.8%)
  1. Abbreviations: HLA-B27 Human leucocyte antigen B27, IBP Inflammatory back pain, IBD Inflammatory bowel disease, NSAID Non-steroidal anti-inflammatory drug, CRP C-reactive protein